ABN 16 165 160 841

ASX RELEASE **29 November 2022**

ACCENT Trial Recruitment Progress

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to advise that it has reached an important recruitment milestone in the Company's ACCENT clinical trial in frontline patients with pancreatic cancer. This week, enrolment of the first cohort of patients was completed.

The first stage of the ACCENT trial is designed to test ascending doses of AMP945 given in combination with standard gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer. Cohorts of patients (three per cohort) are given the same dose of AMP945 in addition to standard chemotherapy so that safety, tolerability, pharmacokinetics and pharmacodynamics of the combined therapy can be assessed. After 1 month of treatment, the trial's Safety Committee will review the clinical data collected for each cohort and, subject to the data, authorise dose escalation of AMP945 in a subsequent cohort.

Amplia's CEO and Managing Director Dr John Lambert commented that "This month, we have opened four additional ACCENT clinical trial sites, taking our total number of sites to seven. There has been a lot of interest in the ACCENT clinical trial and we expect that recruitment rates will accelerate as the trial builds further momentum. We are delighted to have reached today's recruitment milestone and we will make further announcements as we reach future milestones and dose escalate AMP945. As ever, our thanks go to the patients who have consented to participate in the ACCENT trial."

This ASX announcement has been approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information

Dr John Lambert

CEO and Managing Director

info@ampliatx.com

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).